Mandate

Vinge advises AstraZeneca

January 30, 2013

Vinge has advised AstraZeneca in connection with the sale of its research facility in Södertälje to Acturum, a group formed by FAM, the Wallenber foundations’ management company, and PEAB. The transaction covers, among other things, real estate, laboratories, research projects and a significant number of laboratory equipment and is intended to create conditions for future research and enterprise within the entire filed of life science.

Vinge’s team consisted of responsible partner Malin Ohlin and associate Kristina Ekberg and also included partner Patrick Forslund and associates Daniel Unger, Johan Cederblad, Nazli Zia, Peter Alstergren, Claes Henriksson and project assistant Sara Andersson.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025